Skandinaviska Enskilda Banken AB (publ) - CHINA BIOLOGIC PRODS HLDGS I ownership

Quarter-by-quarter ownership
Skandinaviska Enskilda Banken AB (publ) ownership history of CHINA BIOLOGIC PRODS HLDGS I
ValueSharesWeighting
Q1 2021$506,000
+0.2%
4,2750.0%0.00%0.0%
Q4 2020$505,000
-96.1%
4,275
-96.5%
0.00%
-95.6%
Q1 2020$13,094,000
+332.3%
121,319
+204.1%
0.07%
+151.9%
Q4 2018$3,029,000
-6.3%
39,900
-1.2%
0.03%
+8.0%
Q3 2018$3,232,00040,4000.02%
Other shareholders
CHINA BIOLOGIC PRODS HLDGS I shareholders Q3 2023
NameSharesValueWeighting ↓
Kite Lake Capital Management (UK) LLP 207,382$24,135,00076.46%
Maso Capital Partners Ltd 539,597$62,798,00020.20%
York Capital Management Global Advisors, LLC 1,102,163$128,270,0007.40%
HHLR ADVISORS, LTD. 2,751,200$320,185,0003.99%
Dalton Investments, Inc. 15,551$1,810,0001.14%
Athos Capital Ltd 8,290$965,0000.96%
Myriad Asset Management Ltd. 67,019$7,799,0000.94%
Temasek Holdings (Private) Ltd 990,000$115,216,0000.75%
OXFORD ASSET MANAGEMENT LLP 211,646$24,631,0000.68%
AGF Investments America Inc. 12,230$1,423,0000.47%
View complete list of CHINA BIOLOGIC PRODS HLDGS I shareholders